CTNM

Contineum Therapeutics, Inc. (CTNM) has been upgraded to a Zacks Rank #2 (Buy) rating based on upward trends in earnings estimates. The upgrade reflects positivity about the company's earnings outlook and positions it in the top 20% of Zacks-covered stocks, suggesting potential for near-term stock price appreciation.

Bristol Myers Squibb announced mixed Phase III results for admilparant in idiopathic pulmonary fibrosis, meeting its primary endpoint only at the 60-mg dose while failing at 120-mg, causing the stock to decline 2.6%. However, the company reported positive Phase III results for RYZ101 in advanced gastroenteropancreatic neuroendocrine tumors, demonstrating statistically significant improvement in progression-free survival. The mixed outcomes reflect uncertainty about admilparant's dose consistency despite favorable safety profiles.